[Hematological toxicity of ticlopidine? (author's transl)]

Four cases of bone marrow aplasia, with temporary agranulocytosis (one of them fatal) are described in patients treated with Ticlopidine, an anti-aggregating drug prescribed for prevention of thromboembolic disease. These data suggest that a systematic hematological assessment would be required in the first three months after initiation of Ticlopidine therapy.